GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Looking Back at the Year in Research: 2019
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Using Tumor Tissue Samples to Break Down Assumptions About Pancreatic Cancer
Dr. Christine Iacobuzio-Donahue uses tumor tissue samples to study how pancreatic cancer tumors develop, so she can find ways to stop the disease.
Studying One Family’s Mutations May Change Pancreatic Cancer Treatment and Prevention
Dr. Sahar Nissim is studying the genetic mutations in one family predisposed to pancreatic cancer, to find new ways to combat the disease.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
Dr. Michael Pishvaian explains how platinum-based therapy can improve the survival of pancreatic cancer patients with a specific mutation.
GENERATE Study Aims to Improve Genetic Testing and Prevention for Pancreatic Cancer
Dr. Sapna Syngal outlines the GENERATE study, which aims to help families with a risk for pancreatic cancer by providing genetic testing.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
